Left ventricular assist devices as destination therapy in stage D heart failure

• 来源期刊: 老年心脏病学杂志（英文版）
• 年，卷（期）: 2019,（8）
• 页码范围: 592-600
• 页数: 9页
• 语种: 英文
• DOI: 10.11909/j.issn.1671-5411.2019.08.009

摘要

1 Introduction Mechanical circulatory support (MCS) has increasingly become an important management opportunity for patients with stage D heart failure (HF) with remarkable impact on patient survival and quality of life.Early clinical trials have demonstrated improved outcomes of durable left ventricular assist device (LVAD) support compared with optimal medical management.[1] As technology advanced,continuous flow LVADs outperformed pulsatile flow devices in clinical trials and the field migrated to HeartMate (Abbott Laboratories,Abbott Park,IL) and HeartWare (Medtronic,Minneapolis,MN) devices due to their clinical superiority.